1623 results for "LSD"
Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner
Molecules – October 28, 2024
Summary
A compelling finding: Psilocybin's active metabolite, psilocin, a hallucinogen, shows significant potential in modulating brain inflammation. In pharmacology and neuroscience, experiments on microglia-like cells revealed this chemistry, acting on specific receptors, inhibited their phagocytic activity and reduced reactive oxygen species and nitric oxide production. This neurotransmitter receptor influence on behavior is crucial. These drug studies, involving psychedelics and chemical synthesis of alkaloids, suggest psilocin could treat neurodegenerative conditions, offering new avenues in psychology and medicine.
Abstract
Neuroinflammation that is caused by microglia, the main immune cells of the brain, contributes to neurodegenerative diseases. Psychedelics, includi...
Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science
Translational Behavioral Medicine – October 17, 2024
Summary
With FDA anticipating psilocybin therapy approval for depression by 2026, **Psychedelics and Drug Studies** are rapidly advancing. Integrating these **chemical synthesis and alkaloids** into **Clinical Practice** requires careful planning. **Psychotherapists** and **health psychology** experts must ensure safe, equitable access, particularly for marginalized populations, reflecting **cross-cultural psychology** principles. Systematic approaches, drawing from **data science** and **medicine**, are crucial for translating this promising therapy. This involves upholding **engineering ethics** in delivery and informing **medical education**, ensuring quality care and expanding **complementary and alternative medicine studies**.
Abstract
Abstract Psychedelics (e.g., 3,4-Methylenedioxymethamphetamine [MDMA], lysergic acid diethylamide [LSD], psilocybin) are molecules that have the po...
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction
European Addiction Research – September 25, 2024
Summary
Psychedelics offer compelling new hope for treating addiction. A comprehensive review spanning 40 years of Psychedelics and Drug Studies highlights their therapeutic potential in medicine and psychiatry. Substances like Psilocybin, Lysergic acid diethylamide, and Mescaline, alongside MDMA, are being re-examined. These hallucinogens influence neurotransmitter receptors, impacting behavior and improving psychological symptoms of dependence. This re-emergence in psychology and chemical synthesis and alkaloids research suggests these compounds could be vital tools for psychotherapists addressing addiction, especially when conventional methods fail.
Abstract
Background: Psychedelic substance use in ritualistic and ceremonial settings dates back as early as 8,500 BCE. Only in recent years, from the mid-2...
Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents
Neuroscience & Biobehavioral Reviews – September 20, 2024
Summary
Psychedelics show significant potential for treating anxiety and maladaptive memories from aversive stimuli. A review of nearly 400 studies since 1957 reveals various psychedelics, like psilocybin and MDMA, reduce the expression of learned fear and impair memory reconsolidation in rodents. This Neuroscience and Psychology research highlights how Psychedelics and Drug Studies modulate neurotransmitter receptor influence on behavior. Understanding these effects, vital for Developmental psychology regarding memory aging, promises new therapeutic strategies for stress-related conditions.
Abstract
Threatening events and stressful experiences can lead to maladaptive memories and related behaviors. Existing treatments often fail to address thes...
Psychedelics as a potential treatment for tobacco use disorder: a systematic review.
Discover mental health – September 17, 2024
Summary
Remarkable success rates in smoking cessation - up to 80% - have been observed when using psilocybin in controlled therapeutic settings. Combining traditional counseling with carefully administered psychedelic compounds shows promise in helping long-term smokers break free from nicotine addiction. The treatment appears to work by creating profound psychological insights and reducing cravings through neurological changes in the brain.
Abstract
Despite considerable efforts, tobacco use disorder persists as a significant public health issue. The effectiveness of current smoking cessation th...
The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies
Progress in Neuro-Psychopharmacology and Biological Psychiatry – September 07, 2024
Summary
Classical hallucinogens like Psilocybin and Mescaline significantly reduce inflammation in preclinical animal studies. A systematic review of 40 articles, drawn from databases including CINAHL, MEDLINE, PsycINFO, and Web of Science, explored the pharmacology of these tryptophan-derived psychedelics. Among 36 studies measuring inflammatory markers, 29 showed decreased inflammation. However, immune cell activity was mixed across 10 studies. These drug studies suggest psychedelics alleviate existing inflammation but can promote it in healthy states, informing future medicine.
Abstract
Emerging evidence suggests that classical psychedelics possess immunomodulatory and anti-inflammatory properties; however, these effects are yet to...
Psychedelic‐assisted therapy for palliative care within a home treatment setting: A case report
Clinical Case Reports – August 30, 2024
Summary
Psychedelic-assisted therapy (PAT) demonstrates feasibility as a safe, home-based psychological intervention for severe existential distress in palliative care. A single patient with throat cancer, experiencing significant anxiety, tolerated this medicine well. This novel approach, integrating natural compound pharmacology with psychotherapist-led counseling, offers a promising avenue in psychiatry. Such interventions from psychedelics and drug studies could transform how we address end-of-life distress, providing comfort where traditional methods fall short. The successful application suggests a new frontier in medicine.
Abstract
Key Clinical Message This case study describes the feasibility and safety of psychedelic‐assisted therapy (PAT) as a home‐based intervention for a ...
[Psychedelic and dissociative agents in psychiatry: challenges in the treatment].
Der Nervenarzt – September 01, 2024
Summary
Ketamine and psychedelics are emerging as groundbreaking options in mental health care. While ketamine shows remarkable success in treating depression, careful monitoring of side effects and addictive potential remains crucial. Recent approvals in multiple countries highlight growing acceptance, though treatment risks must be balanced against benefits. Current evidence suggests these therapies are safe when properly administered, but study quality varies and protocols need standardization.
Abstract
With the discovery of the antidepressive effects of ketamine and the increasing withdrawal of the pharmaceutical industry from the development of n...
Classic psychedelics and the treatment for alcoholism.
Progress in neuro-psychopharmacology & biological psychiatry – December 20, 2024
Summary
A single dose of classic psychedelics can significantly reduce alcohol dependence, offering hope for those struggling with alcohol use disorder. These substances work by rewiring neural pathways in the brain, helping patients break free from destructive drinking patterns. Clinical trials show remarkable success rates, with many participants maintaining sobriety after treatment. Unlike conventional therapies, psychedelic-assisted treatment appears to address the root causes of dependence, rather than just managing symptoms.
Abstract
Alcohol is a harmful drug, and reducing its consumption is a significant challenge for users. Furthermore, alcohol dependence is often treatment-re...
Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application—a review
Annals of Palliative Medicine – August 22, 2024
Summary
Psychedelic medicine, specifically psilocybin-assisted psychotherapy, offers a powerful new approach to profound existential distress for patients with life-threatening illnesses. Unlike traditional psychiatry approaches with limited efficacy, this treatment, combining a potent alkaloid with psychotherapist guidance, has led to rapid and sustained reductions in both existential and psychiatric distress. Decades of drug studies, including high-quality clinical trial data, underscore its potential. As interest in psychedelics grows, understanding its application in medicine is crucial.
Abstract
Existential distress is commonly experienced by patients diagnosed with a life-threatening illness. This condition has been shown to adversely impa...
Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis
BMJ – August 21, 2024
Summary
High-dose psilocybin, a potent hallucinogen, significantly outperformed escitalopram for depressive symptoms in a systematic review of randomized controlled trials. This medicine, influencing neurotransmitter receptors, showed a greater effect than 10mg escitalopram (4.66 points) and 20mg (4.69 points). While better than placebo, psilocybin's effect size was small (0.31) when compared to traditional antidepressant trials. Crucially, no severe adverse effect, unlike some psychiatry drugs (e.g., Fluoxetine, Risperidone), was more common than placebo. Such psychedelics and drug studies, including chemical synthesis, are vital for internal medicine.
Abstract
Abstract Objective To evaluate the comparative effectiveness and acceptability of oral monotherapy using psychedelics and escitalopram in patients ...
Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA.
Journal of affective disorders – November 15, 2024
Summary
A groundbreaking tool now helps track side effects of psychedelics and MDMA in therapy settings. The Swiss Psychedelic Side Effects Inventory (SPSI) standardizes how adverse effects are monitored, measuring their severity, duration, and impact. Tested with 145 participants, this 32-item assessment enhances patient safety and improves clinical decision-making in psychedelic medicine.
Abstract
Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately assess side effec...
The rising use of cognitive enhancement drugs and predictors of use during COVID-19: findings from a cross-sectional survey of students and university staff in the UK.
Frontiers in psychology – January 01, 2024
Summary
During COVID-19 lockdowns, UK universities saw a striking 42% increase in students using cognitive enhancement drugs like Modafinil. A survey of 736 students and staff revealed significant upticks in psychoactive drug use, including microdosing psychedelics, as people adapted to remote learning. Lower agreeableness and conscientiousness emerged as key personality factors predicting drug use.
Abstract
The use of psychoactive substances to increase cognitive performance while studying has been termed 'pharmacological cognitive enhancement' (PCE). ...
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.
CNS drugs – October 01, 2024
Summary
Psychedelic medicines show promising results in treating addiction, with success rates significantly higher than traditional methods. Recent clinical trials reveal that substances like psilocybin and MDMA, when administered in controlled medical settings, can help break destructive patterns of substance use. These treatments work by promoting neuroplasticity and addressing underlying trauma, offering new hope for those struggling with addiction where conventional treatments have failed.
Abstract
Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, includi...
Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine
Journal of Psychoactive Drugs – June 21, 2024
Summary
A 42-year-old man suffered a hypertensive emergency after combining 1g of *Psilocybe cubensis* mushrooms, a potent hallucinogen, with Tranylcypromine and Dextroamphetamine-Amphetamine medicine. This rare event, observed in drug studies, highlights critical pharmacology concerns. The interaction, possibly involving phenylethylamine—an alkaloid found in the mushrooms—and the prescribed amphetamines, dramatically influenced his neurotransmitter receptors. Despite symptoms of a heart attack, emergency cardiac catheterization revealed no damage. This case underscores the dangers of combining psilocybin with MAOIs and norepinephrine-releasing drugs.
Abstract
Data on medication interactions with psychedelics are limited. Here we present what may be the first published report of a hypertensive emergency f...
Time-resolved coupling between connectome harmonics and subjective experience under the psychedelic DMT
OpenAlex – May 31, 2024
Summary
Psychedelics profoundly alter Consciousness. Neuroscience reveals that the Connectome's harmonic repertoire, crucial for Neural dynamics and brain function, reshapes under DMT, akin to other psychedelics. Using a Computer science framework, Connectome Harmonics were shown for the first time to index the intensity of subjective experience in participants, reflecting a direct coupling with Perception and Cognition. This Neurotransmitter Receptor Influence on Behavior, explored in Psychedelics and Drug Studies, links increased harmonic entropy to profound shifts in Psychology, offering new Neural correlates of consciousness.
Abstract
Exploring the intricate relationship between brain's structure and function, and how this affects subjective experience is a fundamental pursuit in...
Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.
Journal of racial and ethnic health disparities – June 01, 2025
Summary
Income and education levels significantly influence how different racial groups respond to psychedelics for mental health benefits. While white individuals show reduced psychological distress with psychedelic use, minorities experience diminished returns - even at higher socioeconomic levels. Notably, educated, high-income Asian users reported increased distress, highlighting how ethnicity and inequality shape therapeutic outcomes.
Abstract
Growing evidence suggests that the race and ethnic minority population may experience fewer protective effects of psychedelics on mental health. Th...
Sexual minority identifiers and their perception of illicit drug use risks in the US: Results from a National Survey.
Journal of psychiatric research – July 01, 2024
Summary
LGBTQ+ adults consistently view illicit drug use as less risky compared to heterosexual peers, according to comprehensive national survey data from over 200,000 Americans. While most participants across all groups recognized high risks in using drugs like cocaine and heroin, sexual minority individuals were significantly more likely to perceive lower dangers. This perception gap was particularly notable among gay men and bisexual adults, highlighting the need for tailored substance abuse prevention strategies for diverse communities.
Abstract
This study examined the relationship between sexual identities and perception of risks associated with illicit drug use among a nationally represen...
Solving a Mystery with Classical and Dual Photoredox Catalysis: Application of Nickel in the Synthesis of Ergot Alkaloids.
Organic letters – May 24, 2024
Summary
Scientists have achieved a breakthrough in producing ergot alkaloids - naturally occurring compounds with important medicinal properties - using an innovative dual-catalyst approach. By employing nickel instead of traditional palladium catalysts, researchers developed a more efficient way to synthesize these valuable molecules, including precursors to therapeutic compounds. This method resolves previous synthesis challenges and offers a more sustainable path forward.
Abstract
A short synthesis of the ergot alkaloid lysergene and a formal total synthesis of lysergic acid diethylamide (LSD) under the avoidance of palladium...
In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials.
Psychopharmacology – June 01, 2024
Summary
Breakthrough treatments combining psychedelics with assisted therapy are showing remarkable promise in mental health care. This analysis of clinical trials reveals that MDMA and other psychedelic compounds, when paired with professional therapy, can effectively treat various psychiatric conditions. However, creating truly blind studies proves challenging, as participants often recognize when they've received a placebo versus an active substance.
Abstract
Recent years have seen a resurgence in randomized, placebo controlled trials (RCTs) utilizing non-classical psychedelics (e.g. 3,4-methyl enedioxy ...
Discovery and Structure–Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists
Journal of Medicinal Chemistry – April 22, 2024
Summary
Psychedelics show promise for mental health, influencing behavior via neurotransmitter receptor influence on behavior. Their pharmacology involves serotonin agonist activity at the 5-HT receptor. Through careful chemistry and chemical synthesis, a new class of serotonin agonists, 2,5-dimethoxyphenylpiperidines, has been discovered. Structure–activity relationship investigations, considering stereochemistry, identified LPH-5 as a selective 5-HT2A receptor agonist. This advances drug studies by providing new tools to understand how serotonin signaling affects the brain.
Abstract
Classical psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) are showing promising results in clin...
Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens
Dermatitis – April 18, 2024
Summary
Despite growing interest in hallucinogen and psychedelic substances for Medicine, their dermatologic side effects are poorly characterized. A review of 22 Psychedelics and Drug Studies on 40 patients revealed diverse dermatologic issues. Psilocybin, for instance, caused vesicular eruptions in four patients. Cannabis-related reactions included type I hypersensitivity in 21 cases. Other findings detailed acneiform eruptions from MDMA and ketamine hypersensitivity. Characterizing these dermatologic impacts is vital for patient care.
Abstract
Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly charac...
Smartphone swabs as an emerging tool for toxicology testing: a proof-of-concept study in a nightclub.
Clinical chemistry and laboratory medicine – August 27, 2024
Summary
Your smartphone may reveal more than just your digital life. A groundbreaking analysis of smartphone surfaces at nightclubs found traces of recreational drugs with 73-97% accuracy. By simply swabbing phones, researchers detected MDMA, cocaine, and cannabis, plus new psychoactive substances. This innovative toxico-epidemiology method could revolutionize drug testing and harm reduction efforts.
Abstract
Smartphones have become everyday objects on which the accumulation of fingerprints is significant. In addition, a large proportion of the populatio...
Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
American journal of therapeutics
Summary
Psychedelic medicines are reemerging as powerful tools for mental health treatment, with breakthrough results in treating depression, anxiety, and PTSD. Recent clinical trials show promising outcomes, particularly with MDMA for PTSD and psilocybin for depression. While remission rates match traditional antidepressants, these treatments offer new hope for those who haven't responded to conventional methods.
Abstract
Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsy...
Patterns of mean age at drug use initiation by race and ethnicity, 2004-2019.
Journal of substance use and addiction treatment – June 01, 2024
Summary
Recent data reveals a promising trend: the age when people first try drugs is increasing across most racial and ethnic groups. Analysis of the National Survey on Drug Use and Health (2004-2019) shows delayed drug initiation among adolescents, particularly for alcohol, marijuana, and tobacco. However, patterns vary significantly by race and ethnicity, highlighting opportunities for targeted prevention efforts.
Abstract
Adolescent drug use can result in clinically significant psychiatric outcomes later in life mitigated by targeted prevention strategies. While mean...
Exploring Novel Antidepressants Targeting G Protein-Coupled Receptors and Key Membrane Receptors Based on Molecular Structures.
Molecules (Basel, Switzerland) – February 22, 2024
Summary
Scientists have made a breakthrough in depression treatment by studying tiny cellular switches called G protein-coupled receptors. Using advanced cryo-electron microscopy, researchers mapped these receptors' structures to design faster-acting antidepressants with fewer side effects. Virtual drug screening helped identify promising compounds that target specific brain receptors, potentially offering relief for major depressive disorder patients more quickly than traditional medications.
Abstract
Major Depressive Disorder (MDD) is a complex mental disorder that involves alterations in signal transmission across multiple scales and structural...
Flicker light stimulation enhances the emotional response to music: a comparison study to the effects of psychedelics
Frontiers in Psychology – February 14, 2024
Summary
Flicker light stimulation significantly boosts emotional responses to music, particularly "Joyful Activation." Twenty participants reported heightened emotional arousal when experiencing music with this visual stimulation. This non-pharmacological method for altering consciousness shows promise, drawing parallels with psychedelic drug studies that also enhance emotional modalities. Understanding how visual flicker influences brain activity and emotional processing could inform cognitive psychology and neuroscience, hinting at neurotransmitter receptor influence on behavior, a realm often explored through biochemical analysis.
Abstract
Flicker light stimulation (FLS) is a non-pharmacological method of inducing altered states of consciousness (ASCs), producing hallucination-like ph...
Expectancy Effects in Psychedelic Trials.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
Positive expectations may significantly influence outcomes in psychedelic therapy, even with microdosing. When participants believe they'll benefit, they often do - highlighting the complex relationship between mind and medicine. Researchers found that proper trial design and blinding procedures are crucial, as the placebo effect can be particularly strong with psychedelics. This understanding helps optimize therapeutic benefits while improving future treatment protocols.
Abstract
Clinical trials of psychedelic compounds like psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltrptamine (DMT) have forced a reconside...
Evaluation of the sedative effect of intranasal versus intramuscular ketamine in 2-6-year-old uncooperative dental patients.
Dental and medical problems – January 01, 2024
Summary
Helping anxious children stay calm during dental work is crucial, and ketamine sedation offers a solution. A comparison of intranasal and intramuscular delivery methods in young dental patients revealed that muscle injection produced better results. Children showed less movement and crying, while dentists reported improved cooperation. The intramuscular approach proved more effective for safe sedation in pediatric dentistry.
Abstract
Conscious sedation has gained more popularity these days, with different routes of drug administration having various advantages and disadvantages....
Psychedelic Microdosing among Young Adults from Southern California
Journal of Psychoactive Drugs – February 10, 2024
Summary
Nearly one in five young adults attempting psychedelic microdosing actually take standard, psychoactive doses, risking adverse effects. Among 2,396 young adults, only 3% (74 individuals) had ever microdosed, despite 12% awareness. Psilocybin (70%) and lysergic acid diethylamide (57%) were the most common hallucinogens. This underscores the need for Medicine, Psychiatry, and Psychology to provide clear guidance on these chemical synthesis and alkaloids, for both Clinical Psychology and broader Psychedelics and Drug Studies.
Abstract
Despite common depictions in the media, there is little scientific evidence on microdosing psychedelic drugs. We assessed awareness, prevalence, an...
Third-Generation Antipsychotics and Lurasidone in the Treatment of Substance-Induced Psychoses: A Narrative Review.
Healthcare (Basel, Switzerland) – January 29, 2024
Summary
Modern antipsychotic medications show promise in treating psychosis triggered by substance use. Newer drugs like aripiprazole, brexpiprazole, and lurasidone work differently than older treatments, offering better outcomes with fewer side effects. These medications effectively manage hallucinations and delusions while helping patients who struggle with both psychosis and substance use disorders. They're particularly effective for psychosis caused by stimulants and cannabis.
Abstract
This narrative review explores the efficacy and tolerability of third-generation antipsychotics (TGAs)-aripiprazole, cariprazine, brexpiprazole, an...
Intensity of Psychoactive Substance Use Affects the Occurrence of Prodromal Symptoms of Psychosis.
Journal of clinical medicine – January 28, 2024
Summary
Heavy drug use may predict early warning signs of psychosis, according to data from 703 substance users. Higher scores on drug addiction screenings (DUDIT) strongly correlated with increased prodromal symptoms - early indicators that can precede serious mental health conditions. Cannabis, MDMA, and amphetamine users who started earlier in life showed greater risk of developing these concerning symptoms. The findings highlight the link between substance intensity and psychological vulnerability.
Abstract
Psychosis is defined as a series of symptoms that impair the mind and lead to a kind of loss of reference to reality. Development of psychosis is u...
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile
Biological Psychiatry Cognitive Neuroscience and Neuroimaging – February 01, 2024
Summary
Psilocybin shows promise for depression, a compelling finding in the burgeoning field of Psychedelics and Drug Studies. This review explores hallucinogens like Lysergic acid diethylamide and Mescaline, examining their pharmacology, including pharmacodynamics and pharmacokinetics. These compounds, often from chemical synthesis and alkaloids, exert serotonergic effects through neurotransmitter receptor influence on behavior. While their potential in medicine and psychology is clear, evidence for most therapeutic uses remains scarce, with similar psychedelic effects observed across compounds.
Abstract
Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyl...
Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions.
Neuropsychiatric disease and treatment – January 01, 2024
Summary
Emerging research shows psychedelic therapy and trauma-focused psychotherapy share key healing mechanisms for PTSD treatment. A comprehensive review of patient experiences reveals both approaches rely on psychological safety, trust, and readiness to process trauma. Psychedelic treatments offer unique benefits through indirect processing and self-narrative reorganization, while maintaining core therapeutic principles.
Abstract
Post-traumatic stress disorder (PTSD) is associated with significant patient burden. While pharmacotherapies and evidence-based psychotherapy inter...
A choroid plexus apocrine secretion mechanism shapes CSF proteome and embryonic brain development.
bioRxiv : the preprint server for biology – January 16, 2024
Summary
The brain's protective fluid contains crucial proteins released through a newly discovered "cellular shedding" process. Scientists found that specialized cells in the choroid plexus release protein-rich cellular fragments into brain fluid, directly influencing neural development. When disrupted by maternal stress, illness, or certain drugs during pregnancy, this delicate process can alter brain development and affect future social behavior in offspring. This insight reveals how environmental factors during pregnancy may impact fetal brain formation.
Abstract
We discovered that apocrine secretion by embryonic choroid plexus (ChP) epithelial cells contributes to the cerebrospinal fluid (CSF) proteome and ...
Older adults in psychedelic-assisted therapy trials: A systematic review
Journal of Psychopharmacology – January 01, 2024
Summary
Psychedelic-assisted psychotherapy appears safe and well-tolerated for older adults, with no serious adverse events among the 10 participants for whom detailed safety data was available. This systematic review, using MEDLINE and other sources for Psychedelics and Drug Studies, analyzed 36 trials involving 1400 patients. Yet, only 19 (less than 1.4%) were aged 65 or older. While initial findings suggest these substances, often from chemical synthesis and alkaloids, modulating neurotransmitter receptors for behavioral influence, are safe, their potential in geriatric Psychology and Medicine warrants further exploration by psychotherapists.
Abstract
Background: Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, lysergic acid di...
Perceptual Modifying Compounds and Their Potential Therapeutic Applications in Neuropsychiatric Disorders.
ACS medicinal chemistry letters – January 11, 2024
Summary
Breakthrough research reveals how psychedelic compounds reshape brain circuits to combat depression, anxiety, and addiction. These substances promote neural growth and enhance brain plasticity by activating key cellular pathways. Working through the brain's command center, they strengthen connections in areas controlling mood and fear, offering rapid relief where traditional treatments often fall short.
Abstract
Psychedelic compounds, including ketamine and LSD, have gained renewed interest as potential treatments for neuropsychiatric disorders. These compo...
Synthetic surprise as the foundation of the psychedelic experience
Neuroscience & Biobehavioral Reviews – January 15, 2024
Summary
Psychedelics like psilocybin profoundly alter consciousness, a surprising effect potentially explained by a "synthetic surprise" mechanism. This cognitive science theory, integrating neuroscience and computer science, proposes that psilocybin activates one specific 5-HT2A receptor type, enforcing a state of prediction error within the brain's predictive coding framework. This disrupts perception by increasing the precision of sensory input over top-down expectations. This novel understanding offers a powerful new perspective for psychology, suggesting psychedelics could therapeutically disrupt maladaptive patterns.
Abstract
Psychedelic agents, such as LSD and psilocybin, induce marked alterations in consciousness via activation of the 5-HT2A receptor (5-HT2ARs). We hyp...
Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – March 01, 2024
Summary
Inhaled DMT shows promise as a rapid-acting psychedelic, with effects lasting just 10 minutes compared to hours for similar compounds. In this groundbreaking clinical trial, researchers tested different doses of N,N-Dimethyltryptamine in healthy volunteers, finding it both safe and well-tolerated. The dose-response study revealed positive mood effects and manageable physical responses, suggesting potential for treating mood disorders efficiently.
Abstract
Psychedelics are being increasingly examined for their therapeutic potential in mood disorders. While the acute effects of ayahuasca, psilocybin, a...
[Narcotic Use under Probation and Parole Supervision - A longitudinal Study of Risk-group-specific Recidivism under Abstinence Conditions].
Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) – February 01, 2024
Summary
Drug testing over 14 years revealed surprising patterns among probationers and parolees: while only 2.7% tested positive for narcotics, women were more likely than men to use amphetamines. Cannabis (3.7%) and opiates (2.4%) were most common among 18-35 year olds. The study analyzed 13,500 tests from 380 people, offering valuable insights into substance use patterns during court-supervised release.
Abstract
The aim of this long-term study was to record substance-specific prevalences of illegal use of narcotics despite court-imposed abstinence requireme...
Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study.
Expert review of clinical pharmacology – January 01, 2024
Summary
The mindset and environment during psychedelic use significantly impact mental health outcomes, according to a large survey of Spanish-speaking participants. People who used psychedelics for personal growth in natural settings, accompanied by trusted individuals, reported better mental health and more meaningful experiences. Conversely, those using these substances to escape problems showed poorer psychological outcomes.
Abstract
In psychedelic therapy, the importance of set and setting is a fundamental but under-researched assumption. The aim of this study is to correlate v...
A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions.
Psychedelic medicine (New Rochelle, N.Y.) – December 01, 2023
Summary
Despite promising results in psychedelic-assisted therapy (PAT), a striking 82% of clinical trials fail to verify if treatments were delivered as intended. Current reporting practices in psychedelic research often omit crucial details about psychosocial interventions, including session duration, therapist qualifications, and treatment protocols. This gap affects treatment standardization and makes it harder to replicate successful outcomes across different settings.
Abstract
Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychos...
Biological studies of clavine alkaloids targeting CNS receptors
Frontiers in Psychiatry – November 21, 2023
Summary
Potent clavine alkaloids, widely present through plant and fungal interactions, are surprisingly underexplored compared to well-known psychedelics like psilocybin and lysergic acid diethylamide. Their unique pharmacology and biology, influencing various brain receptors, offer vast potential for drug studies. Exploring their chemical synthesis and alkaloids could uncover novel hallucinogen compounds. This neuroscience-focused work highlights opportunities to expand the therapeutic range beyond current lysergic acid derivatives, revolutionizing our understanding of psychedelic action and future drug development.
Abstract
In contrast to well established psychedelics such as lysergic acid diethylamide (LSD) and psilocybin, ergot alkaloids of the clavine subclass have ...
Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis
Journal of Psychoactive Drugs – November 15, 2023
Summary
Depression symptoms saw substantial relief from psychedelics, a meta-analysis of eighteen studies in clinical psychology reveals. Psilocybin therapy showed a large effect size (g = -1.92), while MDMA also significantly impacted depression (g = -0.71). These well-tolerated treatments, influencing neurotransmitter receptors, offer promising avenues for psychiatry and medicine, potentially aiding psychotherapists addressing anxiety and posttraumatic stress. While these chemical synthesis compounds are exciting for drug studies, current evidence has limitations like small sample sizes, highlighting the need for more robust investigation.
Abstract
There has been a resurgence in psychedelic research for managing psychiatric conditions in recent years. This study aimed to present a comprehensiv...
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Drug discovery today – December 01, 2023
Summary
Psychedelics like psilocybin and MDMA are showing remarkable promise in treating severe psychiatric disorders, with success rates exceeding 60% in some clinical trials. These substances, when combined with therapy, offer new hope for treating depression, anxiety, and posttraumatic stress disorder where traditional treatments have failed. Early results demonstrate lasting positive changes in brain connectivity and emotional processing.
Abstract
Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic ag...
The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice.
Frontiers in molecular biosciences – January 01, 2023
Summary
Scientists have discovered that lisuride, a drug that affects serotonin 2A receptors in the brain, shows promise as an antidepressant without typical hallucinogenic effects. Unlike related compounds, it produced minimal head twitch responses in mice while demonstrating lasting mood-improving effects. The drug reduced depression-like behaviors and increased sugar preference, with fewer serotonin-syndrome symptoms than similar medications.
Abstract
There is now evidence from multiple Phase II clinical trials that psychedelic drugs can exert long-lasting anxiolytic, anti-depressant, and anti-dr...
Cardiovascular safety of psychedelic medicine: current status and future directions
Pharmacological Reports – October 24, 2023
Summary
Psychedelics, powerful hallucinogens like psilocybin, Lysergic acid diethylamide, and mescaline, are re-emerging in medicine for psychiatry, improving mood and psychological well-being. Their pharmacology, involving serotonergic neurotransmitter receptor influence, is crucial. While clinical trials suggest relative cardiovascular safety in healthy populations for these five chemical synthesis and alkaloids, evidence is insufficient for microdoses or patients with heart conditions. Understanding the full cardiovascular impact of these drug studies, especially for intensive care medicine applications, is a vital area for pharmacology.
Abstract
Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychi...
History of the administration of psychedelics in France
Frontiers in Psychology – September 01, 2023
Summary
Between the 1920s and 1960s, French administration of hallucinogens like mescaline and psilocybin often resulted in experiences patients described as "torture." Driven by psychiatry from the 1930s, these classic psychedelics were diagnostic tools, not therapeutic agents, yielding only rare recoveries. Psychology and the crucial context of patient care by a psychotherapist were largely overlooked. This historical approach, detailed in Historical and Scientific Studies, explains France's current hesitation during the psychedelic renaissance, contrasting with modern Complementary and Alternative Medicine Studies.
Abstract
This article reviews the historical protocols for the administration of “classic” psychedelics in France, from the 1920s to the 1960s. Taking a chr...
Matrix Effects of Urine Marker Substances in LC-MS/MS Analysis of Drug of Abuse.
Therapeutic drug monitoring – February 01, 2024
Summary
Drug testing accuracy faces an unexpected challenge: common chemicals in urine can interfere with results. Scientists found that polyethylene glycol (PEG), used in urine marking systems, can mask drug detection signals. However, when PEG levels are kept low, testing remains reliable, with accuracy rates above 85% for most substances. This finding helps labs maintain trustworthy drug screening results.
Abstract
Analysis of drug abuse is frequently performed using high-performance liquid chromatography with an MS/MS detector and electrospray ionization. In ...
Use of psychoactive substances by goods carriage drivers associated with Kerala, India.
Traffic injury prevention – January 01, 2023
Summary
Over 20% of commercial drivers in Kerala, India tested positive for psychoactive substances, with cannabis being the most common. Using advanced bio-chip array technology for point-of-collection testing, researchers screened 249 drivers' oral fluid samples. Longer-distance drivers showed higher substance use rates. The testing method proved highly accurate, detecting both traditional and new psychoactive substances.
Abstract
This study aimed to measure the prevalence of drugs of abuse (DOA) among the goods carriage drivers associated with the southern State of India, Ke...
Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study
European Journal of Pain – August 20, 2023
Summary
Many individuals struggling with chronic pain find significant relief using psychedelics, often surpassing conventional medicine. An observational study revealed that full doses of these substances provided better analgesic effects for conditions like fibromyalgia, arthritis, and migraine. Microdoses also offered superior relief for migraine and comparable benefits for fibromyalgia. Interestingly, sciatica was the sole condition where these Complementary and Alternative Medicine approaches didn't outperform standard drug treatments. This highlights a promising avenue for Psychedelics and Drug Studies in pain management.
Abstract
Abstract Background Chronic pain is a major cause of suffering and disability and is often associated with psychiatric complications. Current treat...
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Journal of Psychopharmacology – August 12, 2023
Summary
Chronic microdosing of psychedelics like Lysergic acid diethylamide and Psilocybin may pose a heart valve risk. Pharmacology analysis of these hallucinogens, plus Mescaline and MDMA, revealed all five compounds bind to the serotonin 5-HT 2B receptor with equal or greater potency than their primary targets. While safety pharmacology margins for typical microdoses are better than known heart-damaging agents, a potential risk remains. Forensic Toxicology and Drug Analysis show MDMA's link to valvular heart disease at full doses. This insight into neurotransmitter receptor influence on behavior informs future drug studies and medicine.
Abstract
Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term s...
[Psychedelic Experiences: Phenomenology, Therapeutic Potentials and Explanatory Models].
Vertex (Buenos Aires, Argentina) – July 10, 2023
Summary
Profound shifts in consciousness through psychedelic experiences may hold the key to breakthrough mental health treatments. Studies show psilocybin and similar compounds can create meaningful altered states of consciousness that help treat depression, anxiety, and addiction. Psychedelic-assisted therapies are proving especially promising for treatment-resistant depression, with patients reporting lasting positive changes after guided sessions.
Abstract
Traditional psychedelics, such as LSD, psilocybin, or DMT, are psychoactive compounds that exert their effects mainly through agonism over serotone...
Evaluation of Sensorimotor Gating Deficits in Mice Through Prepulse Inhibition (PPI) of the Startle Response.
Methods in molecular biology (Clifton, N.J.) – January 01, 2023
Summary
Disrupted sensory filtering, a hallmark of several psychiatric disorders, can now be studied using sophisticated behavioral tests in animal models. Scientists found that mice treated with DOI, a compound that mimics certain aspects of psychosis, showed measurable changes in their startle responses. By analyzing prepulse inhibition—how well animals filter out irrelevant sensory information—researchers gained valuable insights into brain mechanisms underlying sensory processing issues common in conditions like schizophrenia.
Abstract
Prepulse inhibition of the startle response enables measuring animal behavior and helps us understand core aspects of neuropsychiatric diseases. Pr...
The G protein biased serotonin 5-HT 2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice.
bioRxiv : the preprint server for biology – June 05, 2023
Summary
Lisuride, a drug that targets serotonin receptors in the brain, shows promise as a potential depression treatment without the hallucinogenic effects common to similar compounds. In experiments with mice, the drug reduced signs of depression, including improved mood-related behaviors and increased interest in rewarding experiences. Unlike related substances, lisuride didn't cause significant head twitches or unusual motor activity, suggesting fewer side effects.
Abstract
There is now evidence from multiple Phase II clinical trials that psychedelic drugs can exert longlasting anxiolytic, anti-depressant, and anti-dru...
In vivo mapping of pharmacologically induced functional reorganization onto the human brain’s neurotransmitter landscape
Science Advances – June 14, 2023
Summary
The human brain's response to drugs reveals a profound link between molecular structure and behavior. Neuroscience shows diverse pharmacological agents, including 10 psychedelics and anesthetics, reorganize brain function by engaging multiple neurotransmitter systems. By mapping 19 neurotransmitter receptors and transporters, a clear influence on behavior emerged. This pharmacology insight has significant implications for Psychology and Medicine, informing drug studies and our understanding of brain disorders. Crucially, regional drug susceptibility mirrors vulnerability to structural alterations seen in conditions like those linked to Tryptophan imbalances.
Abstract
To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage the brain...
Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis
Cureus – May 07, 2023
Summary
A 48-year-old man on ADHD medication suffered a life-threatening arrhythmia, possibly due to *polypharmacy*. This case in *medicine* highlights challenges in *psychiatry* as *psychedelics and drug studies* explore *psilocybin* and other *hallucinogens* like *ecstasy* and *phencyclidine*. Understanding *recreational drug* interactions is vital, especially for conditions like *bipolar disorder* or *hypomania* where *Quetiapine* is used. Comprehensive *forensic toxicology and drug analysis*, including *cannabis* research, is crucial to prevent such adverse events.
Abstract
Recreational drug use is a significant public health concern in various countries. It is well understood that usage of psychedelics/hallucinogens, ...
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics
Therapeutic Advances in Psychopharmacology – January 01, 2023
Summary
Many experience a "psychedelic afterglow" after using hallucinogens like psilocybin, often synthesized alkaloids. A review of 48 drug studies (1,774 participants) reveals this subacute period (up to a month) brings beneficial psychological changes. Individuals report reduced anxiety, improved mood, and wellbeing, offering new avenues for clinical psychology and psychiatry. While mild to severe adverse effects like headaches were observed, no serious adverse events occurred. Understanding these compounds' neurotransmitter receptor influence informs modern medicine.
Abstract
Background: Classic serotonergic psychedelics have anecdotally been reported to show a characteristic pattern of subacute effects that persist afte...
The thalamus in psychosis spectrum disorder.
Frontiers in neuroscience – January 01, 2023
Summary
The thalamus, a deep brain structure that acts like a neural switchboard, plays a crucial role in psychosis. Recent discoveries show how disrupted connections between the thalamus and cortex affect cognition and perception. Studies combining brain imaging and pharmacology reveal that this disruption mirrors effects seen with psychosis-inducing drugs. The mediodorsal nucleus appears particularly important, suggesting new treatment paths for mental health conditions.
Abstract
Psychosis spectrum disorder (PSD) affects 1% of the world population and results in a lifetime of chronic disability, causing devastating personal ...
A whole-brain model of the neural entropy increase elicited by psychedelic drugs.
Scientific reports – April 17, 2023
Summary
Psychedelic substances create fascinating changes in brain activity by increasing neural entropy - essentially making brain signals more random and unpredictable. Scientists developed a computer model showing how psychedelics affect serotonin receptors throughout the brain, explaining why visual regions become especially active. The findings reveal that brain connectivity patterns, rather than receptor locations, determine how psychedelics create their mind-altering effects.
Abstract
Psychedelic drugs, including lysergic acid diethylamide (LSD) and other agonists of the serotonin 2A receptor (5HT2A-R), induce drastic changes in ...